StratAcuity Proud to Complete the Proteostasis Therapeutics Cystic Fibrosis Inaugural Clinical Advisory Board Search

Share Article

StratAcuity, The Science of People: StratAcuity successfully completes the search for the Proteostasis Therapeutics Inaugural Cystic Fibrosis Clinical Advisory Board.

StratAcuity successfully completes the search for the Proteostasis Therapeutics Inaugural Cystic Fibrosis Clinical Advisory Board. The newly appointed board will serve as a strategic resource for the upcoming selection and study of the Company's leading compounds that double the activity of the most effective combination, ivacaftor/lumacaftor in the gold-standard HBE cell assay, for the most common mutation, F508del/F508del, found in the cystic fibrosis population. Read the Proteostasis press release to learn more;

Distinguished members of the Proteostasis Clinical Advisory Board include:

Dr. Richard B. Moss, MD, a Professor Emeritus of Pediatrics at the Lucile Salter Packard Children's Hospital at Stanford University, will serve as Chairman of the Clinical Advisory Board. He is the former Chief of Pediatric Pulmonary and Allergy Divisions, and allergy-immunology and pulmonary fellowship director. Dr. Moss also served as Director of the Cystic Fibrosis Center at Stanford, and site principal investigator for Cystic Fibrosis Therapeutics Development Network, where he was also the inaugural Chair of the Protocol Review Committee from 1991 to 2009.

Dr. Jane C. Davies, MD, FRCPCH, is Professor of Paediatric Respirology and Experimental Medicine at Imperial College, London and an Honorary Consultant in Paediatric Respiratory Medicine at the Royal Brompton & Harefield NHS Foundation Trust. She is the site co-PI for the European CF Society Clinical Trials Network and leads their Lung Clearance Index Core facility. She has experience in clinical trial design for both investigator-initiated and pharma-sponsored studies.

Dr. Michael R. Knowles, MD, is Professor of Pulmonary and Critical Care Medicine at University of North Carolina (UNC), Chapel Hill. He is also the head of two multicenter studies, the first, Genetic modifiers of disease phenotype (severity) in cystic fibrosis lung and liver disease, which also includes a recently formed international consortium that is conducting a whole genome scan. The second is a consortium of eight North American sites studying rare genetic disorders of mucociliary clearance. Additionally, Dr. Knowles was the site PI at UNC Chapel Hill, and served on the Steering Committee, when the Cystic Fibrosis Therapeutic Development Network was founded.

Dr. Felix A. Ratjen, MD, PhD, is the Chief of Paediatric Respiratory Medicine at The Hospital for Sick Children, Professor of Paediatrics at The University of Toronto, and Senior Scientist at the Research Institute in the Department of Physiology and Experimental Medicine. He co-leads the Cystic Fibrosis Centre at The Hospital for Sick Children, and is the Medical Director of the Clinical Research Unit there.

Dr. Isabelle Sermet-Gaudelus, MD, PhD, is Professor of Pediatric Medicine at l'Hôpital Necker-Enfants Malades in Paris, France. She has developed and conducted several therapeutic trials for cystic fibrosis for both academic and company-initiated investigations. Her research focuses on modulation of the clinical severity of cystic fibrosis depending on fluid transfer and its therapeutic applications.

Dr. Pamela L. Zeitlin, MD, PhD, is Professor and Director of Pediatric Pulmonary Medicine and the Co-Director of the Cystic Fibrosis Center at Johns Hopkins University. Her research focuses on the role of chloride channels in inherited diseases of the respiratory tract, especially cystic fibrosis.

The search was led by Patrick Marshall, CBO for StratAcuity.

About StratAcuity
Born in 2000 StratAcuity partners with an elite group of biopharmaceutical companies in Boston and San Diego through our retained, contingency and temp/contract placement services ranging from executive leadership to research associates. StratAcuity’s difference is the relationships we’ve nurtured, the reputation we earned, a propriety recruitment process and a world-class recruitment team possessing real world expertise in Discovery, Development, Clinical Operations & Regulatory Affairs.

At StratAcuity, we connect companies to candidates, candidates to careers and careers to scientific advancement. When you need the best to work for you, seek the best to work with you. Chemistry is everything.™

About Proteostasis Therapeutics
Proteostasis is a drug discovery company addressing diseases caused by defects in protein folding, trafficking and clearance for orphan and neurodegenerative diseases. The Company’s Disease Relevant Translation (DRT™) platform combines a proprietary screening approach with state-of-the-art medicinal chemistry, to generate highly selective drug candidates and is advancing a pipeline inclusive of a lead program in cystic fibrosis and a partnership with Biogen Idec for neurodegenerative diseases.

The Company’s DRT™ platform utilizes functionally disease relevant cellular models with high translatability to develop therapies based on the modulation of protein homeostasis pathways within the cell. These pathways are part of cellular ‘quality control’ machinery, known as the protein homeostasis network or Proteostasis Network (PN). By modifying the function and capacity of the PN, the Company’s therapeutic product candidates correct for imbalances in the PN resulting from the cumulative effects of disease, genetic mutations, environmental factors and aging. For more information visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patrick Marshall/CBO
+1 (603) 766-0600
Email >

Aimee Turcotte
Visit website